echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 34 chemicals companies in the first half of the net profit growth, who makes more money?

    34 chemicals companies in the first half of the net profit growth, who makes more money?

    • Last Update: 2020-11-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    As of August 31, all 344 listed companies in the pharmaceutical and biological sector have released their 2020 half-yearly reports, of which 78 are chemical agents.
    34 of these 78 companies had year-on-year net profit attributable to shareholders of listed companies.
    , Yuheng Pharmaceuticals, Lu Anti-Pharmaceuticals, Huaren Pharmaceuticals grew rapidly, Hengrui Pharmaceuticals net profit exceeded 2.6 billion yuan, while East China Pharmaceuticals, Jilin Yandong net profit exceeded 1 billion yuan.
    below the author will take you to see the details of these enterprises.
    34 chemical preparation enterprises in the first half of the net profit growth (Photo: Pharmaceutical Network) Yuheng Pharmaceuticals net profit increased by 188.02% YoY Yuheng Pharmaceuticals is a pharmaceutical industry as the main line, pharmaceutical business as the core, covering scientific research, production, marketing and other fields of high-tech enterprise groups.
    Among chemicals companies, Yuheng Pharmaceuticals' net profit increased significantly in the first half of this year, with revenue of RMB1.405 billion, down 58.61% YoY, but net profit attributable to shareholders of listed companies was RMB669 million, up 188.02% YoY.
    regarding the decline in revenue, Yuheng Pharmaceuticals said that due to the impact of the outbreak, the company and the industry upstream and downstream delayed resumption of work, personnel, logistics constraints, product demand decline, the company's operating performance decreased compared to the same period last year.
    , sales of some products declined as a result of pharmaceutical industry policies.
    As for the increase in net profit, Yuheng Pharmaceuticals previously said in its earnings forecast that this was due to the related proceeds from the sale of a 100% stake in Ano (China) Pharmaceutical Co., Ltd. during the reporting period, and that the non-recurring profit and loss of the sale had an impact on net profit of about 687 million yuan;
    Net Profit of Lu Anti-Pharmaceuticals increased by 179.55% YoY, and Lu Anti-Pharmaceutical's main business was human antibiotics, veterinary antibiotics and others.
    on the evening of August 28th, Lu Anti-Pharma released its semi-annual results report, reporting that the net profit attributable to shareholders of listed companies in the first half of 2020 was about 228 million yuan, up 179.55 percent year-on-year, and operating income was about 1,999 million yuan, up 7.87 percent year-on-year.
    In the first half of 2020, Lu anti-medicine first-hand grasp of epidemic prevention and control, one-handed recovery of work, around the development strategy and business plan, all staff unity, face up to difficulties, and strive to overcome the market demand reduction, poor logistics and transportation, raw materials supply shortage and other effects, the orderly progress of all work, to maintain the basic stability of production and operation.
    the introduction, the company to strengthen fine management, the implementation of full-time work law to improve labor efficiency, through the integration of sales channels, do a good job of volume procurement and supply, promote the increment of new products and a series of measures to hedge the profit factors.
    at the same time actively strive for the national preferential enterprise policy, access to the national epidemic low interest rate loans of 200 million yuan, to supplement liquidity, reduce costs.
    Huaren Pharmaceuticals' net profit increased by 170.83% YoY Huaren Pharmaceuticals was mainly engaged in the development, production and sales of non-PVC soft bag high-volume preparations (basic infusions, therapeutic infusions, peritina dialysis fluids) and raw materials, ancillary pharmaceutical packages, medical devices and other products.
    According to the semi-annual report released by Huaren Pharmaceuticals, Huaren Pharmaceuticals achieved operating income of RMB586,456,924.75 in the first half of 2020, down 17.61% YoY, but realized net profit attributable to shareholders of listed companies of RMB35,113,672.82, up 170.83% YoY.
    It is understood that in the first half of 2020, Huaren Pharmaceuticals actively respond to difficulties, on the one hand, to do a good job of prevention and control, resumption of production, to ensure product stability, timely supply, do a good job of stock customer maintenance and management, on the other hand, seize market opportunities, increase the development of new customers, further expand the incremental market, through the joint efforts of the whole staff, the business gradually recovered.
    Hengrui Pharmaceuticals to make more money, net profit reached 2.662 billion yuan in the first half of 2020 the pharmaceutical industry to make more money is still the industry a brother Hengrui Pharmaceutical.
    data show that in the first half of this year, Hengrui Pharmaceutical's economic indicators grew steadily, achieving revenue of 11.309 billion yuan, up 12.78 percent year-on-year, while net profit attributable to shareholders of listed companies reached 2.662 billion yuan, up 10.34 percent year-on-year, still maintaining the level of earning more than 14 million yuan a day.
    the development of Hengrui Pharmaceuticals is mainly due to the company's innovation results and product structure optimization, shadow agents as the representative of the company's non-anti-tumor products maintained a stable growth trend.
    , in terms of research and development innovation, Hengrui Pharmaceuticals invested 1,863 million yuan in research and development during the reporting period, up 25.56 percent year-on-year, with research and development spending accounting for 16.48 percent of revenue.
    has set up research and development centers and clinical medicine departments in Lianyungang, Shanghai, Chengdu and the United States, established enterprise technology centers and postdoctoral research stations, national molecularly targeted drug engineering research center, the national "major new drug creation" special incubator base, annual research and development investment accounted for more than 10% of revenue, research and development team of more than 3400 people.
    East China Pharmaceuticals' net profit was about 1,731 million yuan on the evening of August 27, the semi-annual results report said that in the first half of 2020, the net profit attributable to shareholders of listed companies was about 1.731 billion yuan, up 8.45 percent year-on-year, and operating income was about 16.661 billion yuan, down 8.7 percent year-on-year.
    this year, East China's pharmaceutical research and development spending continued to grow, the first half of the pharmaceutical industry investment of 474 million yuan, an increase of 2.50% year-on-year.
    company's research and development projects go ahead as planned and is expected to continue to grow throughout the year.
    is understood that in the core varieties of Akapo sugar, East China Medicine said Akapo sugar chewing tablets are now in the national market normal sales, sales in the month-to-month increase.
    said it would strive for full-year sales of Acapo sugar products not to be lower than last year's level.
    addition, the company's diabetes key varieties of pyridine metformin tablets and cardiovascular key varieties of pyridine tablets doubled in the first half of this year.
    Jilin Yandong's net profit was about 1.020 billion yuan on the evening of August 28, Jilin Yandong released a semi-annual results report, the first half of 2020 its net profit attributable to shareholders of listed companies was about 1.020 billion yuan, up 16.97 percent year-on-year, and operating income was about 1.121 billion yuan, down 31.73 percent year-on-year.
    It is understood that Jilin Yudong is mainly engaged in traditional Chinese medicine, biochemical drug research and development, manufacturing and sales, while expanding health food, food, aquaculture, planting and other fields, and gradually developed into a "industry and finance" two-wheel drive model of the holding group listed companies, Jilin Yandong in the capital market has an in-depth layout.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.